Latest Pharma and Biotech News
Biotechnology
27 June 2025 In a significant showcase for investors, BeOne Medicines announced major advancements to its industry-leading oncology pipeline during an investor R&D Day.
Today's issue
Refine Search
Pharmaceutical
US biotech Arbutus Biopharma has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), in China, ending a nearly four-year partnership with Qilu Pharmaceutical. 27 June 2025
Biotechnology
Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. 27 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Biosimilars
German biosimilars company Formycon has announced that its 2025/2029 corporate bond was significantly oversubscribed due to high demand, leading to an increase in the initially targeted issuance volume from 50 million euros ($59 million) to 70 million euros. 27 June 2025
Biotechnology
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). 27 June 2025
Pharmaceutical
Despite calls for the meeting to be delayed, Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) went ahead. 27 June 2025
Biotechnology
In a significant showcase for investors, BeOne Medicines announced major advancements to its industry-leading oncology pipeline during an investor R&D Day. 27 June 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Biosimilars
Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL. 27 June 2025
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical today revealed that it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for an additional indication of its anti-cancer agent/ALK inhibitor Alecensa (alectinib) for ALK fusion/rearrangement gene-positive unresectable advanced or recurrent solid tumors, including pediatric patients. 27 June 2025
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Pharmaceutical
US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive’ top-line results from the IMPACT Phase IIb trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). 27 June 2025
Biotechnology
US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention product, Enflonsia (clesrovimab), as a majority of an influential advisory panel voted to recommend its use in newborns ahead of the 2025-2026 RSV season. 27 June 2025
Pharmaceutical
Rising use of innovative medicines and shifting spending patterns are reshaping the global pharmaceutical landscape, according to a new report from US data analytics group IQVIA. 27 June 2025
Biotechnology
US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. 26 June 2025
Generics
US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb, accusing the drugmaker of manipulating the patent system to preserve its monopoly on the multiple myeloma treatment Pomalyst (pomalidomide). 26 June 2025
Biotechnology
Singapore-based biotech Hummingbird Bioscience has out-licensed its lead immunotherapy candidate, HMBD-002, to Australian drug developer Percheron Therapeutics in a deal valued at up to $290 million. 26 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer and Spikevax (COVID-19 Vaccine, mRNA) manufactured Moderna to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines. 26 June 2025
Biotechnology
Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform. 26 June 2025
Biotechnology
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim findings from a Phase I study. 26 June 2025
All news
Pharmaceutical
US biotech Arbutus Biopharma has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), in China, ending a nearly four-year partnership with Qilu Pharmaceutical. 27 June 2025
Biotechnology
Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. 27 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Biosimilars
German biosimilars company Formycon has announced that its 2025/2029 corporate bond was significantly oversubscribed due to high demand, leading to an increase in the initially targeted issuance volume from 50 million euros ($59 million) to 70 million euros. 27 June 2025
Biotechnology
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). 27 June 2025
Pharmaceutical
Despite calls for the meeting to be delayed, Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) went ahead. 27 June 2025
Biotechnology
In a significant showcase for investors, BeOne Medicines announced major advancements to its industry-leading oncology pipeline during an investor R&D Day. 27 June 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Biosimilars
Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL. 27 June 2025
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical today revealed that it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for an additional indication of its anti-cancer agent/ALK inhibitor Alecensa (alectinib) for ALK fusion/rearrangement gene-positive unresectable advanced or recurrent solid tumors, including pediatric patients. 27 June 2025
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Pharmaceutical
US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive’ top-line results from the IMPACT Phase IIb trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). 27 June 2025
Biotechnology
US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention product, Enflonsia (clesrovimab), as a majority of an influential advisory panel voted to recommend its use in newborns ahead of the 2025-2026 RSV season. 27 June 2025
Pharmaceutical
Rising use of innovative medicines and shifting spending patterns are reshaping the global pharmaceutical landscape, according to a new report from US data analytics group IQVIA. 27 June 2025
Biotechnology
US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. 26 June 2025
Generics
US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb, accusing the drugmaker of manipulating the patent system to preserve its monopoly on the multiple myeloma treatment Pomalyst (pomalidomide). 26 June 2025
Biotechnology
Singapore-based biotech Hummingbird Bioscience has out-licensed its lead immunotherapy candidate, HMBD-002, to Australian drug developer Percheron Therapeutics in a deal valued at up to $290 million. 26 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer and Spikevax (COVID-19 Vaccine, mRNA) manufactured Moderna to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines. 26 June 2025
Biotechnology
Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform. 26 June 2025
Biotechnology
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim findings from a Phase I study. 26 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze